Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback